Contact Us
Drug Search Results
More Filters [+]

SIG-007

Alternative Names: sig-007, sig 007, sig007
Latest Update: 2021-03-05
Latest Update Note: News Article

Product Description

SIG-007 is comprised of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A, or AGAL for the treatment of Fabry disease. (Sourced from: https://ir.sigilon.com/news-releases/news-release-details/sigilon-therapeutics-receives-orphan-drug-designation-sig-007)

Mechanisms of Action: Cell Therapy

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: Injection

FDA Designation: Orphan Drug - Fabry Disease *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sigilon Therapeutics
Company Location: CAMBRIDGE MA 02142
Company CEO: Rogerio Vivaldi Coelho
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SIG-007

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 0: Fabry Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title

03/05/2021

News Article

 Sigilon Therapeutics Receives Orphan Drug Designation for SIG-007 for the Treatment of Fabry Disease

02/08/2021

News Article

 Sigilon Therapeutics Announces Preclinical Data in Multiple Lysosomal Diseases at the 17th Annual WORLDSymposium™

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions